

10657011

(FILE 'HOME' ENTERED AT 19:57:23 ON 18 JUL 2005)

FILE 'REGISTRY' ENTERED AT 19:57:35 ON 18 JUL 2005

L1 1 S OXYCODONE/CN
L2 1 S HYDROCODONE/CN

FILE 'CAPLUS, USPATFULL' ENTERED AT 20:15:50 ON 18 JUL 2005

L3 1226 S L1
L4 53277 S HYDROXYPROPYL CELLULOSE OR HYDROXYPROPYLMETHYL CELLULOSE OR H
L5 134 S L3 AND L4
L6 1902 S CATION RESIN
L7 4297 S CATIONIC RESIN
L8 59869 S ION EXCHANGE RESIN
L9 45 S L8 AND L5
L10 0 S L7 AND L5
L11 0 S L6 AND L5
L12 29674 S AMBERLITE
L13 7 S L12 AND L5
L14 7 DUP REM L13 (0 DUPLICATES REMOVED)
L15 9 S L3 AND L12
L16 7 S L15 AND L4

Blessing

10219027

L2 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
RN 125-29-1 REGISTRY
ED Entered STN: 16 Nov 1984
CN Morphinan-6-one, 4,5-epoxy-3-methoxy-17-methyl-, (5α)- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Codeinone, dihydro- (6CI)
CN ~~Dicodid~~ (7CI)
CN Morphinan-6-one, 4,5α-epoxy-3-methoxy-17-methyl- (8CI)

OTHER NAMES:

CN ~~(-)-Dihydrocodeinone~~
CN 6-Oxo-7,8-dihydrocodeine
CN Bekadid
CN Dihydrocodeinone
CN Hydrocodon
CN **Hydrocodone**
CN Multacodin
CN NSC 19044

FS STEREOSEARCH

DR 9007-52-7, 1037-91-8, 50678-79-0

MF C18 H21 N O3

CI COM


LC STN Files: ADISNEWS, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSChem, DDFU, DIOGENES, DRUGU, EMBASE, HODOC*, HSDB*, IFICDB, IFIPAT, IFIUDb, IMSPATENTS, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PIRA, PROMT, PS, RTECS*, SPECINFO, TOXCENTER, USAN, USPAT2, USPATFULL, VETU

(*File contains numerically searchable property data)

Other Sources: EINECS**, WHO

(**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry. Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

879 REFERENCES IN FILE CA (1907 TO DATE)
27 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
879 REFERENCES IN FILE CAPLUS (1907 TO DATE)
16 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

Blessing

10219027

ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN

RN 76-42-6 REGISTRY

ED Entered STN: 16 Nov 1984

CN Morphinan-6-one, 4,5-epoxy-14-hydroxy-3-methoxy-17-methyl-, (5 α)-(9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Codeinone, 7,8-dihydro-14-hydroxy- (6CI, 7CI)

CN Morphinan-6-one, 4,5 α -epoxy-14-hydroxy-3-methoxy-17-methyl- (8CI)

OTHER NAMES:

CN (-)-Oxycodone

CN 14-Hydroxydihydrocodeinone

CN 3-O-(Methyl)oxymorphone

CN 6-Oxo-14-hydroxy-7,8-dihydrocodeine

CN 7,8-Dihydro-14-hydroxycodeinone

CN Dihydro-14-hydroxycodeinone

CN Dihydrohydroxycodeinone

CN Dihydrone

CN NSC 19043

CN Oxicon

CN Oxycodeinone

CN Oxycodone

CN Oxymorphone 3-methyl ether

FS STEREOSEARCH

MF C18 H21 N O4

CI COM


LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHM, DDFU, DIOGENES, DRUGU, EMBASE, GMELIN*, HSDB*, IFICDB, IFIPAT, IFIUDB, IMSCOSEARCH, IMSPATENTS, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PHAR, PROMT, PROUSDDR, PS, RTECS*, SPECINFO, TOXCENTER, USAN, USPAT2, USPATFULL

(*File contains numerically searchable property data)

Other Sources: EINECS**, WHO

(**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

879 REFERENCES IN FILE CA (1907 TO DATE)

24 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

884 REFERENCES IN FILE CAPLUS (1907 TO DATE)

32 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

Blessing

10219027

=> s hydrocodone/cn

L2 1 HYDROCODONE/CN

Blessing

WEST Search History

DATE: Monday, July 18, 2005

Hide?	<u>Set</u> <u>Name</u>	<u>Query</u>	<u>Hit</u> <u>Count</u>
<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ</i>			
<input type="checkbox"/>	L22	maloney-ann\$.in.	3
<input type="checkbox"/>	L21	5980882.pn.	2
<input type="checkbox"/>	L20	L19 and l8	3
<input type="checkbox"/>	L19	L18 and l16	76
<input type="checkbox"/>	L18	L17 or l4	621
<input type="checkbox"/>	L17	divinylbenzene near20 methacrylic acid	494
<input type="checkbox"/>	L16	L15 and divinylbenzene	1280
<input type="checkbox"/>	L15	L14 and l6	9315
<input type="checkbox"/>	L14	hydroxypropyl cellulose or hydroxypropylmethyl cellulose or hydroxyethyl cellulose	40153
<input type="checkbox"/>	L13	hydrocodone	1805
<input type="checkbox"/>	L12	IRP-70	7
<input type="checkbox"/>	L11	L10 and l8	1
<input type="checkbox"/>	L10	methacrylic acid-divinyl benzene	36
<input type="checkbox"/>	L9	L8 and l4	5
<input type="checkbox"/>	L8	oxycodone	1866
<input type="checkbox"/>	L7	L6 and l5	23
<input type="checkbox"/>	L6	methacrylic acid	112198
<input type="checkbox"/>	L5	L4 and l3	46
<input type="checkbox"/>	L4	IRP-64 or IRP-88	133
<input type="checkbox"/>	L3	IRP-69	119
<i>DB=PGPB; PLUR=YES; OP=ADJ</i>			
<input type="checkbox"/>	L2	IRP-68	0
<input type="checkbox"/>	L1	20040062812.pn.	1

END OF SEARCH HISTORY

10219027

L15 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:492436 CAPLUS
DOCUMENT NUMBER: 139:57960
TITLE: Abuse-resistant sustained-release opioid formulation
INVENTOR(S): Maloney, Ann; Murwin, Debra Marie; Schobelock, Michael Jay
PATENT ASSIGNEE(S): Roxane Laboratories, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 11 pp., Cont.-in-part of U.S. Ser. No. 85,597.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003118641	A1	20030626	US 2002-264020	20021003
US 2002164373	A1	20021107	US 2002-85597	20020227
PRIORITY APPLN. INFO.:			US 2000-626584	B1 20000727
			US 2002-85597	A2 20020227
			US 1999-146298P	P 19990729
			WO 2000-US20413	W 20000727
AB	A method for reducing the abuse potential of an oral dosage form of an opioid extractable by commonly available household solvents comprises combining a therapeutically effective amount of the opioid compound, or a salt thereof, a matrix-forming polymer and an ionic exchange resin. Tablet comps. contained oxycodone-HCl, lactose, Amberlite IRP69M, Methocel K100M, Cab-O-Sil, and stearic acid.			
AB	A method for reducing the abuse potential of an oral dosage form of an opioid extractable by commonly available household solvents comprises combining a therapeutically effective amount of the opioid compound, or a salt thereof, a matrix-forming polymer and an ionic exchange resin. Tablet comps. contained oxycodone-HCl, lactose, Amberlite IRP69M, Methocel K100M, Cab-O-Sil, and stearic acid.			
IT	81296-15-3, Amberlite IRP69M RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (abuse-resistant sustained-release opioid formulation)			
IT	57-27-2, Morphine, biological studies 57-42-1, Meperidine 76-41-5, Oxymorphone 76-42-6, Oxycodone 76-57-3, Codeine 76-99-3, Methadone 124-90-3, Oxycodone hydrochloride 125-28-0, Dihydrocodeine 143-71-5, Hydrocodone bitartrate 359-83-1, Pentazocine 466-99-9, Hydromorphone 1639-60-7, Propoxyphene hydrochloride 17140-78-2, Propoxyphene napsylate 42408-82-2, Butorphanol RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (abuse-resistant sustained-release opioid formulation)			

L15 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:100956 CAPLUS
DOCUMENT NUMBER: 134:152650
TITLE: Opioid sustained-release formulations
INVENTOR(S): ~~Maloney~~, Ann M.
PATENT ASSIGNEE(S): Roxane Laboratories, Inc., USA
SOURCE: PCT Int. Appl., 30 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English

Blessing

10219027

FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001008661	A2	20010208	WO 2000-US20413	20000727
WO 2001008661	A3	20010322		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2379987	AA	20010208	CA 2000-2379987	20000727
EP 1204406	A2	20020515	EP 2000-950755	20000727
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2003522127	T2	20030722	JP 2001-513391	20000727
US 2002164373	A1	20021107	US 2002-85597	20020227
US 2004062812	A1	20040401	US 2003-657011	20030905
PRIORITY APPLN. INFO.:				
			US 1999-146298P	P 19990729
			US 2000-626584	A1 20000727
			WO 2000-US20413	W 20000727
			US 2002-85597	B1 20020227
AB	Disclosed is a solid, oral, controlled release dosage form comprising a therapeutically effective amount of an opioid compound, or a salt thereof, a matrix-forming polymer and an ionic exchange resin. A sustained-release tablet (180 mg each) contained oxycodone hydrochloride 16.7, lactose 12.8, Methocel K100M 55, Na polystyrene sulfonate 10, Cab-O-Sil 0.5, and stearic acid 5 %.			
IT	57-27-2, Morphine, biological studies 57-42-1, Meperidine 76-41-5, Oxymorphone 76-42-6, Oxycodone 76-57-3, Codeine 76-99-3, Methadone 124-90-3, Oxycodone hydrochloride 125-28-0, Dihydrocodeine 143-71-5, Hydrocodone bitartrate 359-83-1, Pentazocine 466-99-9, Hydromorphone 1639-60-7, Propoxyphene hydrochloride 9003-70-7, Divinylbenzene-styrene copolymer 9004-62-0, Hydroxyethyl cellulose 9004-64-2, Hydroxypropyl cellulose 9004-65-3, Hydroxypropyl methyl cellulose 9080-79-9, Sodium polystyrene sulfonate 17140-78-2, Propoxyphene napsylate 42408-82-2, Butorphanol 50602-21-6, Divinylbenzene-methacrylic acid copolymer 55464-99-8, Amberlite IRP 69 81296-15-3, Amberlite IRP 69M			
RL:	(ThU (Therapeutic use); BIOL (Biological study); USES (Uses) (opioid sustained-release oral solid formulations))			
L15 ANSWER 3 OF 9 USPATFULL on STN				
ACCESSION NUMBER:	2005:44329 USPATFULL			
TITLE:	Methods and materials for the treatment of pain comprising opioid antagonists			
INVENTOR(S):	Burns, Lindsay H., San Francisco, CA, UNITED STATES Schoenhard, Grant L., San Carlos, CA, UNITED STATES			
	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2005038062	A1	20050217	
APPLICATION INFO.:	US 2004-825257	A1	20040414 (10)	

Blessing

10219027

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-463004P	20030414 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Janet M. McNicholas, Ph.D., McAndrews, Held & Malloy, Ltd., 34th Floor, 500 West Madison Street, Chicago, IL, 60661	
NUMBER OF CLAIMS:	272	
EXEMPLARY CLAIM:	1	
LINE COUNT:	2752	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods and compositions for treating subjects with pain, including neuropathic pain, using opioid antagonists or combinations of opioid antagonists and opioid agonists, including, for example, wherein the amount of an opioid antagonist enhances the neuropathic pain-alleviating potency of an opioid agonist.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

DETD . . . as bentonite, microcrystalline cellulose (e.g., Avicel), methyl cellulose, carboxymethylcellulose calcium, sodium carboxymethylcellulose, alginic acid, sodium alginate, cellulose polyacrilin potassium (e.g., Amberlite), alginates, sodium starch glycolate, gums, agar, guar, locust bean, karaya, xanthan, pectin, tragacanth, agar, bentonite, and other materials known to . . .

IT 57-27-2, Morphine, biological studies 57-42-1, Meperidine 76-41-5, Oxymorphone 76-42-6, Oxycodone 76-57-3, Codeine 76-99-3, Methadone 125-29-1, Hydrocodone 437-38-7, Fentanyl 465-65-6, Naloxone 466-99-9, Hydromorphone 469-62-5, Propoxyphene 16590-41-3, Naltrexone 27203-92-5, Tramadol 55096-26-9, Nalmefene 71195-58-9, Alfentanil
(opioid antagonists alone or in combinations with opioid agonists for treatment of pain)

L15 ANSWER 4 OF 9 USPATFULL on STN

ACCESSION NUMBER: 2004:285859 USPATFULL

TITLE: Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats

INVENTOR(S): Schoenhard, Grant L., San Carlos, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004224020	A1	20041111
APPLICATION INFO.:	US 2003-742672	A1	20031218 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-434839P	20021218 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Janet M. McNicholas, McAndrews, Held & Malloy, Ltd., 34th Floor, 500 W. Madison Street, Chicago, IL, 60661	
NUMBER OF CLAIMS:	104	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	3 Drawing Page(s)	
LINE COUNT:	3762	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to oral dosage form with active agents in

Blessing

10219027

controlled release cores and in immediate release gelatin capsule coats.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

DETD . . . methyl cellulose, carboxymethylcellulose calcium, sodium carboxymethylcellulose, hydroxy propylcellulose-low substituted, colloidal silicon dioxide, alginic acid, sodium alginate, cellulose polyacrilin potassium (e.g., **Amberlite**), alginates, sodium starch glycolate, gums, agar, guar, locust bean, karaya, xanthan, pectin, tragacanth, agar, bentonite, polyvinylpyrrolidone and other materials known.

IT 76-42-6, Oxycodone 16590-41-3, Naltrexone
(oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats)

L15 ANSWER 5 OF 9 USPATFULL on STN

ACCESSION NUMBER: 2004:82362 USPATFULL

TITLE: Opioid sustained release formulation

INVENTOR(S): Maloney, Ann M., Dublin, OH, UNITED STATES

PATENT ASSIGNEE(S): Roxane Laboratories, Inc., Columbus, OH (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004062812	A1	20040401
APPLICATION INFO.:	US 2003-657011	A1	20030905 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2002-85597, filed on 27 Feb 2002, ABANDONED Continuation of Ser. No. US 2000-626584, filed on 27 Jul 2000, ABANDONED		

	NUMBER	DATE
PRIORITY INFORMATION:	WO 2000-US20413	20000727
	US 1999-146298P	19990729 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	BOEHRINGER INGELHEIM CORPORATION, 900 RIDGEBURY ROAD, P O BOX 368, RIDGEFIELD, CT, 06877	
NUMBER OF CLAIMS:	43	
EXEMPLARY CLAIM:	1	
LINE COUNT:	868	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A solid, oral, controlled release dosage form comprising a therapeutically effective amount of an opioid compound, or a salt thereof, a matrix-forming polymer and an ionic exchange resin.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM . . . size, significantly improves the sustained release profile of the present formulations as compared to the regular particle size resins (e.g. **Amberlite** IRP-69M vs. **Amberlite** IRP-69). For example, biostudies of formulations using fine particle size resin suggest sustained-release formulations of the present invention may provide.

DETD . . . having the formulations given in Table I below were prepared as follows: oxycodone hydrochloride, USP, lactose NF (Flast Flo), and **Amberlite** IRP 69M fine particle size cationic exchange resin were run through a No. 20 mesh screen for delumping and were. . . mg/

	10 mg/	10 mg/	10 mg/
Hydrochloride	tablet	tablet	tablet
Lactose, NF	27.8% w/w	25.8% w/w	31.1% w/w

	10 mg/	10 mg/	10 mg/
Hydrochloride	tablet	tablet	tablet
Lactose, NF	27.8% w/w	25.8% w/w	31.1% w/w

Blessing

10219027

(Fast Flo)

Amberlite IRP	5.0% w/w	7.0% w/w	6.7% w/w
20.0% w/w			
69 M Fine			
Particle Size			
Methocel	55.0% w/w	55.0% w/w	50.0% w/w
K100.			50.0% w/w

DETD . . . Aluminum Lake 5285 for 10 minutes. The lactose/color mix was then milled. Cab-O-Sil (M-5) (a glidant), oxycodone hydrochloride USP and **Amberlite** IRP-69M fine particle size were passed through a No. 20 mesh screen for delumping and were then mixed with the. . .
 FORMULA 5 FORMULA 6

Oxycodone	30 mg/	30 mg/
Hydrochloride	tablet	tablet
Lactose, NF	12.3% w/w	14.5% w/w
(Fast Flo)		
Amberlite IRP	10.0% w/w	5.0% w/w
69 M Fine		
Particle Size		
Methocel	55.0% w/w	55.0% w/w
K100 M		
(Premium) CR		
(hydroxylpropyl		

DETD [0050] Example formulations of Oxycodone Hydrochloride Sustained Release Tablets (10 mg of active) were prepared using various particle sizes of **Amberlite** IRP 69. The specific formulations are set forth in Table 7. The function of each ingredient is also described.

TABLE. . . Hydrochloride, USP Active 6.7 6.7

	Ingredient		
Lactose, NF (Fast Flo)	Diluent	27.8	27.8
Methocel K100M (Premium) CR	SR Matrix	55	55
(Hydroxypropyl	Former		
Methylcellulose, USP)			
Amberlite IRP 69 (Sodium	SR Matrix	5	--
Polystyrene Sulfonate, USP)	Aid		
Amberlite IRP 69 (Sodium	SR Matrix	--	0.5
Polystyrene Sulfonate, USP) sieve	Aid		
fraction retained on 100 mesh			
screen			
Amberlite IRP 69 (Sodium	SR Matrix	--	4.5
Polystyrene Sulfonate, USP) sieve	Aid		
fraction through 325 mesh screen			
Cab-O-Sil (M-5)	Glidant.	0.5	0.5
Stearic Acid, . . .			

DETD [0051] Oxycodone Hydrochloride, USP, Lactose, NF (Fast Flo), and **Amberlite** IRP 69 (Sodium Polystyrene Sulfonate, USP) are passed through a #20 mesh screen for delumping and are mixed for 10. . .

DETD [0054] Particle Size Data for various grades and sieve fractions of **Amberlite** IRP 69 (Sodium Polystyrene Sulfonate, USP) are set forth in Table 9.

TABLE 9

		Particle size	Particle size
	Mean particle	(U.S. Standard	range
Grade	size (µm)	mesh)	(microns)

Blessing

10219027

Amberlite IRP 69 M (Sodium Polystyrene Sulfonate, USP) Fine Particle Size	27	NLT 90% through 325 mesh	<2 to 97
Amberlite IRP 69 (Sodium Polystyrene Sulfonate, USP)	57	100-400	<10 to 228
Amberlite IRP 27 µm 27 Fine Particle Size		NLT 90% through 325 mesh	<2 to 81
Amberlite IRP 69 (Sodium Polystyrene Sulfonate, USP) sieved through 325 mesh	23*	100% through 325 mesh	<5 to 53*

NLT = Not Less Than.

*Electrozone.

IT 57-27-2, Morphine, biological studies 57-42-1, Meperidine 76-41-5,
Oxymorphone 76-42-6, Oxycodone 76-57-3, Codeine 76-99-3,
Methadone 124-90-3, Oxycodone hydrochloride 125-28-0, Dihydrocodeine
143-71-5, Hydrocodone bitartrate 359-83-1, Pentazocine 466-99-9,
Hydromorphone 1639-60-7, Propoxyphene hydrochloride 9003-70-7,
Divinylbenzene-styrene copolymer 9004-62-0, Hydroxyethyl cellulose
9004-64-2, Hydroxypropyl cellulose 9004-65-3, Hydroxypropyl methyl
cellulose 9080-79-9, Sodium polystyrene sulfonate 17140-78-2,
Propoxyphene napsylate 42408-82-2, Butorphanol 50602-21-6,
Divinylbenzene-methacrylic acid copolymer 55464-99-8, Amberlite IRP 69
81296-15-3, Amberlite IRP 69M
(opioid sustained-release oral solid formulations)

L15 ANSWER 6 OF 9 USPATFULL on STN

ACCESSION NUMBER: 2003:271539 USPATFULL

TITLE: Opioid antagonist compositions and dosage forms

INVENTOR(S): Sherman, Barry, Hillsborough, CA, UNITED STATES
Remien, Mary, San Francisco, CA, UNITED STATES
Barbiér, Remi, San Francisco, CA, UNITED STATES
McGinity, James W., Austin, TX, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003191147	A1	20031009
APPLICATION INFO.:	US 2002-119615	A1	20020409 (10)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	MCANDREWS HELD & MALLOY, LTD, 500 WEST MADISON STREET, SUITE 3400, CHICAGO, IL, 60661		
NUMBER OF CLAIMS:	171		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	6 Drawing Page(s)		
LINE COUNT:	3686		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to novel dosage forms, pharmaceutical compositions, kits, and methods of administration of an opioid antagonist in an amount of at least about 0.0001 mg to about or less than about 1.0 mg, including from about 0.0001 mg to less than about 0.5 mg. Solid oral dosage forms are disclosed consisting essentially of an opioid antagonist or alternatively comprising an opioid antagonist and another active ingredient, such as an opioid agonist. Immediate release oral dosage forms are disclosed that release all or a substantial percentage of opioid antagonist, and another active ingredient when

Blessing

10219027

present, in a desired time. Concurrent release dosage forms are disclosed that provide concurrent release of an opioid antagonist and another active ingredient.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

DETD . . . as bentonite, microcrystalline cellulose (e.g., Avicel), methyl cellulose, carboxymethylcellulose calcium, sodium carboxymethylcellulose, alginic acid, sodium alginate, cellulose polyacrilin potassium (e.g., **Amberlite**), alginates, sodium starch glycolate, gums, agar, guar, locust bean, karaya, xanthan, pectin, tragacanth, agar, bentonite, and other materials known to. . .

IT 57-42-1, Meperidine 76-41-5, Oxymorphone 76-42-6, Oxycodone 76-57-3, Codeine 76-99-3, Methadone 103-90-2, Acetaminophen 124-90-3, Roxicodone 125-29-1, Hydrocodone 143-71-5, Hydrocodone bitartrate 437-38-7, Fentanyl 465-65-6, Naloxone 466-99-9, Hydromorphone 469-62-5, Propoxyphene 27203-92-5, Tramadol 36282-47-0, Ultram 55096-26-9, Nalmefene 71195-58-9, Alfentanil 609769-49-5
(opioid antagonist compns.)

L15 ANSWER 7 OF 9 USPATFULL on STN

ACCESSION NUMBER: 2003:172797 USPATFULL

TITLE: Abuse-resistant sustained-release opioid formulation

INVENTOR(S): Maloney, Ann, Dublin, OH, UNITED STATES

Murwin, Debra Marie, Orient, OH, UNITED STATES

Schobelock, Michael Jay, Grove City, OH, UNITED STATES

PATENT ASSIGNEE(S): Roxane Laboratories, Inc., Columbus, OH (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003118641	A1	20030626
APPLICATION INFO.:	US 2002-264020	A1	20021003 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2002-85597, filed on 27 Feb 2002, PENDING Continuation of Ser. No. US 2000-626584, filed on 27 Jul 2000, ABANDONED		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	BOEHRINGER INGELHEIM CORPORATION, 900 RIDGEBURY ROAD, P O BOX 368, RIDGEFIELD, CT, 06877		
NUMBER OF CLAIMS:	6		
EXEMPLARY CLAIM:	1		
LINE COUNT:	954		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method for reducing the abuse potential of an oral dosage form of an opioid extractable by commonly available household solvents said method comprising combining a therapeutically effective amount of the opioid compound, or a salt thereof, a matrix-forming polymer and an ionic exchange resin.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM . . . significantly improves both the sustained release profile of the present formulations as compared to the regular particle size resins (e.g. **Amberlite** IRP-69M vs. **Amberlite** IRP-69) and its resistance to extraction by commonly available household solvents, in particular isopropyl alcohol, vodka, white vinegar, hot water, . . .

DETD . . . having the formulations given in Table I below were prepared as follows: oxycodone hydrochloride, USP, lactose NF (Flast Flo), and **Amberlite** IRP 69M fine particle size cationic exchange resin

Blessing

were run through a No. 20 mesh screen for delumping and were. . . 4

Oxycodone Hydrochloride	10	mg/tablet	10	mg/tablet
10	mg/tablet	10	mg/tablet	
Lactose, NF (Fast Flo)	27.8%	w/w	25.8%	w/w
31.1%	w/w	10.8%	w/w	
Amberlite IRP 69M Fine Particle Size	5.0%	w/w	7.0%	
w/w	6.7%	w/w	20.0%	w/w
Methocel K100M (Premium) CR	55.0%	w/w	55.0%	w/w.

DETD . . . Aluminum Lake 5285 for 10 minutes. The lactose/color mix was then milled. Cab-O-Sil (M-5) (a glidant), oxycodone hydrochloride USP and Amberlite IRF 69M fine particle size were passed through a No. 20 mesh screen for delumping and were then mixed with. . . to form tablets.

TABLE 3

INGREDIENT	FORMULA 5		FORMULA 6	
Oxycodone Hydrochloride	30	mg/tablet	30	mg/tablet
Lactose, NF (Fast Flo)	12.3%	w/w	14.5%	w/w
Amberlite IRP 69M Fine Particle Size	10.0%	w/w	5.0%	w/w
Methocel K100M (Premium) CR (hydroxylpropyl methylcellulose, USP)	55.0%	w/w	55.0%	w/w
D and C Yellow No..				

DETD . . . the following formulation:

Oxycodone Hydrochloride	40	mg
Lactose, NF (Fast Flo)	16.1%	w/w
Methocel K 100M	45.5%	w/w
Amberlite IPR 69M	12.5%	w/w
Cab-O-Sil	1.1%	w/w
Stearic Acid, NF	5.0%	w/w

ED and C Yellow No 6 Aluminum Lake. . .

DETD . . . mark. Oxycodone Hydrochloride, USP Cab-O-Sil (M-5)

Cab-O-Sil (M-5)

.check mark. Lactose, NF (Fast Flo) Oxycodone Hydrochloride, USP
Oxycodone Hydrochloride, USP

Amberlite (IRP 69 M Fine Particle Size) (Sodium Polystyrene Sulfonate, USP)
Amberlite IRP 69M Fine Particle Size (Sodium Polystyrene Sulfonate, USP)
Step 3

IT 57-27-2, Morphine, biological studies 57-42-1, Meperidine 76-41-5, Oxymorphone 76-42-6, Oxycodone 76-57-3, Codeine 76-99-3, Methadone 124-90-3, Oxycodone hydrochloride 125-28-0, Dihydrocodeine 143-71-5, Hydrocodone bitartrate 359-83-1, Pentazocine 466-99-9, Hydromorphone 1639-60-7, Propoxyphene hydrochloride 17140-78-2, Propoxyphene napsylate 42408-82-2, Butorphanol
(abuse-resistant sustained-release opioid formulation)

10219027

L15 ANSWER 8 OF 9 USPATFULL on STN

ACCESSION NUMBER: 2002:294331 USPATFULL
TITLE: Opioid sustained-released formulation
INVENTOR(S): Maloney, Ann M., Dublin, OH, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002164373	A1	20021107
APPLICATION INFO.:	US 2002-85597	A1	20020227 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2000-626584, filed on 27 Jul 2000, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	WO 2000-US20413	20000727
	US 1999-146298P	19990729 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	BOEHRINGER INGELHEIM CORPORATION, 900 RIDGEBURY ROAD, P O BOX 368, RIDGEFIELD, CT, 06877	
NUMBER OF CLAIMS:	43	
EXEMPLARY CLAIM:	1	
LINE COUNT:	872	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A solid, oral, controlled release dosage form comprising a therapeutically effective amount of an opioid compound, or a salt thereof, a matrix-forming polymer and an ionic exchange resin.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

DETD . . . size, significantly improves the sustained release profile of the present formulations as compared to the regular particle size resins (e.g. **Amberlite** IRP-69M vs. **Amberlite** IRP-69). For example, biostudies of formulations using fine particle size resin suggest sustained-release formulations of the present invention may provide.

DETD . . . having the formulations given in Table I below were prepared as follows: oxycodone hydrochloride, USP, lactose NF (Fast Flo), and **Amberlite** IRP 69M fine particle size cationic exchange resin were run through a No. 20 mesh screen for delumping and were. . . 3
FORMULA 4

Oxycodone	10	mg/tablet	10	mg/tablet	10	mg/tablet
10	mg/tablet					
Hydrochloride						
Lactose, NF	27.8%	w/w	25.8%	w/w	-31.1%	w/w
10.8%	w/w					
(Fast Flo)						
Amberlite IRP	5.0%	w/w	7.0%	w/w	6.7%	
w/w	20.0%	w/w				
69 M Fine						
Particle Size						
Methocel	55.0%	w/w	55.0%	w/w	50.0%	w/w
50.0%	w/w					
K100.						

DETD . . . 6 Aluminum Lake 5285 for 10 minutes. The lactose/color mix was-then milled. Cab-O-Sil (M-5) (a glidant), oxycodone hydrochloride USP and **Amberlite** IRP-69M fine particle size were passed through a No. 20 mesh screen for delumping and were then mixed with the.

Blessing

10219027

and compressed to form tablets.

TABLE 3

INGREDIENT	FORMULA 5		FORMULA 6	
Oxycodone Hydrochloride	30	mg/tablet	30	mg/tablet
Lactose, NF (Fast Flo)	12.3%	w/w	14.5%	w/w
Amberlite IRP 69 M Fine Particle Size	10.0%	w/w	5.0%	w/w
Methocel K100 M (Premium) CR (hydroxylpropyl methylcellulose, USP)	55.0%	w/w	55.0%	w/w
D and C Yellow No.	0.4%	w/w	--	

DETD [0052] Example formulations of Oxycodone Hydrochloride Sustained Release Tablets (10 mg of active) were prepared using various particle sizes of Amberlite IRP 69. The specific formulations are set forth in Table 7. The function of each ingredient is also described.

TABLE. . . Hydrochloride, USP	Active Ingredient	6.7	6.7
Lactose, NF (Fast Flo)	Diluent	27.8	27.8
Methocel K100M (Premium) CR (Hydroxypropyl Methylcellulose, USP)	SR Matrix Former	55	55
Amberlite IRP 69 (Sodium Polystyrene Sulfonate, USP)	SR Matrix Aid	5	--
Amberlite IRP 69 (Sodium Polystyrene Sulfonate, USP) sieve fraction retained on 100 mesh screen	SR Matrix Aid	--	0.5
Amberlite LRP 69 (Sodium Polystyrene Sulfonate, USP) sieve fraction through 325 mesh screen	SR Matrix Aid	--	4.5
Cab-O-Sil (M-5)	Glidant	0.5	0.5
Stearic Acid, . . .			

DETD [0054] Oxycodone Hydrochloride, USP, Lactose, NF (Fast Flo), and Amberlite IRP 69 (Sodium Polystyrene Sulfonate, USP) are passed through a #20 mesh screen for delumping and are mixed for 10.

DETD [0057] Particle Size Data for various grades and sieve fractions of Amberlite IRP 69 (Sodium Polystyrene Sulfonate, USP) are set forth in Table 9.

TABLE 9

Grade	Mean particle size (µm)	Particle size (US Standard mesh)	Particle size range (microns)
Amberlite IRP 69M (Sodium Polystyrene Sulfonate, USP) Fine	27	NLT 90% through 325 mesh	<2 to 97

Blessing

10219027

Particle Size

Amberlite IRP 69 57 100-400 <10 to 228
(Sodium Polystyrene Sulfonate, USP)

Amberlite IRP 27 μ m 27 NLT 90% through <2 to 81
Fine Particle Size 325 mesh

Amberlite IRP 69 23* 100% through <5 to 53*
(Sodium Polystyrene Sulfonate, USP) sieved
through 325 mesh

NLT = Not Less Than

*Electrozone.

IT 57-27-2, Morphine, biological studies 57-42-1, Meperidine 76-41-5,
Oxymorphone 76-42-6, Oxycodone 76-57-3, Codeine 76-99-3,
Methadone 124-90-3, Oxycodone hydrochloride 125-28-0, Dihydrocodeine
143-71-5, Hydrocodone bitartrate 359-83-1, Pentazocine 466-99-9,
Hydromorphone 1639-60-7, Propoxyphene hydrochloride 9003-70-7,
Divinylbenzene-styrene copolymer 9004-62-0, Hydroxyethyl cellulose
9004-64-2, Hydroxypropyl cellulose 9004-65-3, Hydroxypropyl methyl
cellulose 9080-79-9, Sodium polystyrene sulfonate 17140-78-2,
Propoxyphene napsylate 42408-82-2, Butorphanol 50602-21-6,
Divinylbenzene-methacrylic acid copolymer 55464-99-8, Amberlite IRP 69
81296-15-3, Amberlite IRP 69M
(opioid sustained-release oral solid formulations)

L15 ANSWER 9 OF 9 USPATFULL on STN

ACCESSION NUMBER: 2002:186092 USPATFULL

TITLE: Active agent delivery systems and methods for
protecting and administering active agents

INVENTOR(S): Piccariello, Thomas, Blacksburg, VA, UNITED STATES
Olon, Lawrence P., Bristol, TN, UNITED STATES
Kirk, Randal J., Radford, VA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002099013	A1	20020725
APPLICATION INFO.:	US 2001-933708	A1	20010822 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-274622P	20010308 (60)
	US 2000-247621P	20001114 (60)
	US 2000-247620P	20001114 (60)
	US 2000-247595P	20001114 (60)
	US 2000-247594P	20001114 (60)
	US 2000-247635P	20001114 (60)
	US 2000-247634P	20001114 (60)
	US 2000-247606P	20001114 (60)
	US 2000-247607P	20001114 (60)
	US 2000-247608P	20001114 (60)
	US 2000-247609P	20001114 (60)
	US 2000-247610P	20001114 (60)
	US 2000-247611P	20001114 (60)
	US 2000-247702P	20001114 (60)
	US 2000-247701P	20001114 (60)
	US 2000-247700P	20001114 (60)
	US 2000-247699P	20001114 (60)
	US 2000-247698P	20001114 (60)

Blessing

US 2000-247807P	20001114 (60)
US 2000-247833P	20001114 (60)
US 2000-247832P	20001114 (60)
US 2000-247927P	20001114 (60)
US 2000-247926P	20001114 (60)
US 2000-247930P	20001114 (60)
US 2000-247929P	20001114 (60)
US 2000-247928P	20001114 (60)
US 2000-247797P	20001114 (60)
US 2000-247805P	20001114 (60)
US 2000-247804P	20001114 (60)
US 2000-247803P	20001114 (60)
US 2000-247802P	20001114 (60)
US 2000-247801P	20001114 (60)
US 2000-247800P	20001114 (60)
US 2000-247799P	20001114 (60)
US 2000-247798P	20001114 (60)
US 2000-247561P	20001114 (60)
US 2000-247560P	20001114 (60)
US 2000-247559P	20001114 (60)
US 2000-247558P	20001114 (60)
US 2000-247556P	20001114 (60)
US 2000-247612P	20001114 (60)
US 2000-247613P	20001114 (60)
US 2000-247614P	20001114 (60)
US 2000-247615P	20001114 (60)
US 2000-247616P	20001114 (60)
US 2000-247617P	20001114 (60)
US 2000-247633P	20001114 (60)
US 2000-247632P	20001114 (60)
US 2000-247631P	20001114 (60)
US 2000-247630P	20001114 (60)

DOCUMENT TYPE: Utility
 FILE SEGMENT: APPLICATION
 LEGAL REPRESENTATIVE: Robert M. Schulman, Esq., Hunton & Williams, Suite
 1200, 1900 K Street, N.W., Washington, DC, 20006-1100
 NUMBER OF CLAIMS: 40
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 8 Drawing Page(s)
 LINE COUNT: 2048
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A composition comprising a polypeptide and an active agent covalently attached to the polypeptide. Also provided is a method for delivery of an active agent to a patient comprising administering to the patient a composition comprising a polypeptide and an active agent covalently attached to the polypeptide. Also provided is a method for protecting an active agent from degradation comprising covalently attaching the active agent to a polypeptide. Also provided is a method for controlling release of an active agent from a composition comprising covalently attaching the active agent to the polypeptide.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

DETD . . . and the supernatant discarded leaving behind a white-yellow residue. The residue was dissolved in 0.3 ml H.sub.2O and shaken with Amberlite IRA-400. The resin was removed by filtration and washed with 3 ml H.sub.2O. The combined eluent and wash were dried.

DETD . . . the supernatant discarded. The pellet was dried overnight in vacuum and then dissolved in 0.3 ml H.sub.2O and shaken with

Amberlite IRA-400. The resin was removed by filtration and washed with 3 ml H.sub.2O. The combined eluent and wash were dried.

IT 50-06-6, Phenobarbital, biological studies 50-18-0, Cyclophosphamide
 50-35-1, Thalidomide 50-44-2, Mercaptopurine 50-78-2, Acetylsalicylic
 acid 50-81-7, Vitamin C, biological studies 51-21-8, Fluorouracil
 51-61-6, Dopamine, biological studies 51-63-8, Dextroamphetamine
 sulfate 51-98-9, Norethindrone acetate 52-01-7, Spironolactone
 52-24-4, Thiotepa 52-86-8, Haloperidol 53-36-1, Methylprednisolone
 Acetate 54-31-9, Furosemide 55-63-0, Nitroglycerin 57-63-6, Ethinyl
 estradiol 58-08-2, Caffeine, biological studies 58-18-4,
 Methyltestosterone 58-25-3, Chlordiazepoxide 58-33-3, Promethazine
 hydrochloride 58-55-9, Theophylline, biological studies 58-61-7,
 Adenosine, biological studies 58-93-5, Hydrochlorothiazide 59-42-7,
 Phenylephrine 60-54-8, Tetracycline 60-87-7, Promethazine 64-31-3,
 Morphine Sulfate 67-20-9, Nitrofurantoin 67-92-5, Dicyclomine
 hydrochloride 68-19-9, Vitamin B12 68-22-4, Norethindrone 71-58-9,
 Medroxyprogesterone acetate 71-68-1, Hydromorphone hydrochloride
 74-79-3, Arginine, biological studies 76-41-5, Oxymorphone
 76-42-6, Oxycodone 76-58-4, Ethylmorphine 78-44-4,
 Carisoprodol 84-02-6, Prochlorperazine maleate 87-08-1, Penicillin V
 87-33-2, Isosorbide Dinitrate 89-57-6, Mesalamine 90-82-4,
 Pseudoephedrine 93-14-1, Guaifenesin 113-45-1, Methylphenidate
 113-52-0 113-92-8, Chlorpheniramine maleate 114-07-8, Erythromycin
 124-90-3, Oxycodone hydrochloride 125-28-0, Dihydrocodeine 125-29-1,
 Hydrocodone 125-33-7, Primidone 125-71-3, Dextromethorphan
 128-13-2, Ursodiol 129-06-6, Warfarin Sodium 132-17-2, Benztropine
 methanesulfonate 143-52-2, Methyl dihydromorphinone 143-71-5,
 Hydrocodone bitartrate 152-11-4, Verapamil hydrochloride 297-76-7,
 Ethynodiol diacetate 298-46-4, Carbamazepine 298-59-9,
 Methylphenidate hydrochloride 303-49-1, Clomipramine 315-30-0,
 Allopurinol 318-98-9, Propranolol Hydrochloride 378-44-9,
 Betamethasone 379-79-3, Ergotamine Tartrate 437-38-7, Fentanyl
 439-14-5, Diazepam 446-86-6, Azathioprine 466-99-9, Hydromorphone
 469-62-5, Propoxyphene 509-60-4, Dihydromorphine 514-36-3,
 Fludrocortisone acetate 541-15-1, Levocarnitine 549-18-8,
 Amitriptyline hydrochloride 554-13-2, Lithium Carbonate 561-27-3,
 Diacetylmorphine 595-33-5, Megestrol acetate 604-75-1, Oxazepam
 630-93-3, Sodium phenytoin 657-24-9, Metformin 745-65-3, Alprostadil
 747-36-4, Hydroxychloroquine sulfate 797-63-7, Levonorgestrel
 846-49-1, Lorazepam 846-50-4, Temazepam 894-71-3, Nortriptyline
 hydrochloride 959-24-0, Sotalol hydrochloride 1134-47-0, Baclofen
 1403-66-3, Gentamicin 1404-93-9, Vancomycin hydrochloride 1501-84-4,
 Rimantadine hydrochloride 1508-65-2, Oxybutynin chloride 1622-61-3,
 Clonazepam 1665-48-1, Metaxalone 1744-22-5, Riluzole 1951-25-3,
 Amiodarone 2078-54-8, Propofol 2152-34-3, Pemoline 2375-03-3,
 Methylprednisolone sodium succinate 4205-91-8 4682-36-4, Orphenadrine
 citrate 4759-48-2, Isotretinoin 5786-21-0, Clozapine 6202-23-9,
 Cyclobenzaprine hydrochloride 6493-05-6, Pentoxifylline 6533-00-2,
 Norgestrel 7280-37-7, Estropipate 7414-83-7, Etidronate disodium
 9002-60-2, Adrenocorticotrophic hormone, biological studies 9002-69-1,
 Relaxin 9005-49-6, Heparin, biological studies 9014-42-0,
 Thrombopoietin 9039-53-6, Urokinase 9041-08-1, Dalteparin sodium
 9041-92-3, . α .1-Protease inhibitor 9080-79-9, Sodium polystyrene
 sulfonate 10238-21-8, Glyburide 11005-12-2, β -Phytosterol
 11056-06-7, Bleomycin 11140-85-5, Glucagon hydrochloride 13311-84-7,
 Flutamide 13614-98-7, Minocycline hydrochloride 14124-50-6,
 Hydrochlorothiazide-triamterene mixture 14611-52-0, Selegiline
 hydrochloride 14838-15-4, Phenylpropanolamine 15307-79-6, Diclofenac

sodium 15663-27-1, Cisplatin 15686-71-2, Cephalexin 17140-78-2,
 Propoxyphene napsylate 17560-51-9, Metolazone 18559-94-9, Albuterol
 19767-45-4, Mesna 20537-88-6, Amifostine 20830-75-5, Digoxin
 21062-37-3D, analogs 21256-18-8, Oxaprozin 21829-25-4, Nifedipine
 22071-15-4, Ketoprofen 23031-32-5, Terbutaline sulfate 25316-40-9,
 Doxorubicin hydrochloride 25322-68-3, Polyethylene glycol 25332-39-2,
 Trazodone hydrochloride 25614-03-3, Bromocriptine 26159-34-2,
 Naproxen sodium 26787-78-0, Amoxicillin 27164-46-1, Cefazolin sodium
 27314-97-2, Tirapazamine 28860-95-9, Carbidopa 28981-97-7, Alprazolam
 29094-61-9, Glipizide 29354-16-3, Thyronine, iodo- 31677-93-7,
 Bupropion hydrochloride 32222-06-3, Calcitriol 32780-64-6, Labetalol
 hydrochloride 33069-62-4, Paclitaxel 33286-22-5, Diltiazem
 hydrochloride 33419-42-0, Etoposide 33564-30-6, Cefoxitin sodium
 34552-83-5, Loperamide hydrochloride 34580-13-7, Ketotifen
 35189-28-7, Norgestimate 36282-47-0, Tramadol hydrochloride
 36505-84-7, Buspirone 36791-04-5, Ribavirin 37296-80-3, Colestipol
 hydrochloride 38398-32-2, Ganaxolone 41340-25-4, Etodolac
 41575-94-4, Carboplatin 42200-33-9, Nadolol 42617-41-4, Activated
 protein C 42924-53-8, Nabumetone 49562-28-9, Fenofibrate
 49842-07-1, Tobramycin sulfate 50370-12-2, Cefadroxil 50700-72-6,
 Vecuronium bromide 51321-79-0, Sparfloxacin 51481-61-9, Cimetidine
 51773-92-3, Mefloquine hydrochloride 52232-67-4, Teriparatide
 53885-35-1, Ticlopidine hydrochloride 53994-73-3, Cefaclor
 54024-22-5, Desogestrel 54143-56-5, Flecainide acetate 54182-58-0,
 Sucralfate 54910-89-3, Fluoxetine 54965-24-1, Tamoxifen citrate
 55079-83-9, Acitretin 56180-94-0, Acarbose 56238-63-2, Cefuroxime
 sodium 57109-90-7, Clorazepate dipotassium 57248-88-1, Pamidronate
 disodium 57852-57-0, Idarubicin hydrochloride 58579-51-4, Anagrelide
 hydrochloride 58786-99-5, Butorphanol tartrate 59122-46-2,
 Misoprostol 59703-84-3, Piperacillin sodium 59729-32-7, Citalopram
 hydrobromide 59865-13-3, Cyclosporin 59989-18-3, Eniluracil
 60142-96-3, Gabapentin 60205-81-4, Ipratropium 60748-06-3, Gastrin 17
 61718-82-9, Fluvoxamine maleate 62288-83-9, Desmopressin acetate
 62571-86-2, Captopril 63074-08-8, Terazosin hydrochloride 63675-72-9,
 Nisoldipine 64221-86-9, Imipenem 64461-82-1, Tizanidine hydrochloride
 64485-93-4, Cefotaxime sodium 64544-07-6, Cefuroxime axetil
 65277-42-1, Ketoconazole 65646-68-6, Fenretinide 65807-02-5,
 Goserelin 66085-59-4, Nimodipine 66104-22-1, Pergolide 66357-35-5,
 Ranitidine 66722-44-9, Bisoprolol 67889-72-9, Acetaminophen-codeine
 phosphate mixture 67992-58-9, Sodium ioxaglate 68562-41-4, Mecasermin
 68693-11-8, Modafinil 68844-77-9, Astemizole 69655-05-6, Didanosine
 70458-96-7, Norfloxacin 70476-82-3, Mitoxantrone hydrochloride
 72509-76-3, Felodipine 72558-82-8, Ceftazidime 72956-09-3, Carvedilol
 73334-07-3, Iopromide 73573-87-2, Formoterol 73590-58-6, Omeprazole
 74103-06-3, Ketorolac 74191-85-8, Doxazosin
 (comps. comprising a polypeptide and an active agent)

=>